Clinical Trials
Search our team at AdventHealth Research Institute
Showing 1 - 5 of 5 clinical trials matching your search
-
NCT07225946
A Phase 3 Randomized, Open-label Study of JNJ-78278343, a T Cell-redirecting agent targeting Human Kallikrein 2, with Docetaxel Versus Docetaxel for Metastatic Castration-Resistant Prostate Cancer (KLK2-PASenger)
This study is currently enrolling.Associated Conditions: GenitourinaryResearch Area: Clinical Cancer ResearchResearch Location: Orlando -
NCT07011719
A Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
This study is currently enrolling.Associated Conditions: GenitourinaryResearch Area: Clinical Cancer ResearchResearch Location: OrlandoThe purpose of this research is to determine whether the investigational drug casdatifan combined with cabozantinib, is well tolerated and effective at treating patients with clear cell renal cell...
-
NCT04724018
Combinatons of Sacituzumab govitecan plus enfortumab vedotin and pembrolizumab for metastatic urothelial carcinoma: the Double Antibody Drug conjugate (DAD) and Double Antibody Drug Conjugate with Immunotherapy (DAD-IO) Phase I/II trial
This study is currently enrolling.Associated Conditions: GenitourinaryResearch Area: Clinical Cancer ResearchResearch Location: OrlandoThis research is being done to study the safety and efficacy of two drug combinations. The first combination is Sacituzumab govitecan and enfortumab vedotin, and the second is Sacituzumab govitecan in... -
NCT05987241
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer A032103
This study is currently enrolling.Associated Conditions: GenitourinaryResearch Area: Clinical Cancer ResearchResearch Location: OrlandoThis study is being done to answer the following question: After having your bladder surgically removed after being diagnosed with bladder cancer, can we better identify which patients need an... -
NCT06305767
A Phase 2, Randomized, Double-blind Study of Adjuvant V940 (mRNA-4157) + Pembrolizumab (MK-3475) vs. Placebo + Pembrolizumab for High-Risk Muscle-Invasive Urothelial Carcinoma (MIUC) Post-Radical Resection
This study is currently enrolling.Associated Conditions: GenitourinaryResearch Area: Clinical Cancer ResearchResearch Location: OrlandoTo compare V940 plus pembrolizumab to placebo plus pembrolizumab with respect to DFS. Hypothesis (H1): V940 plus pembrolizumab is superior to placebo plus pembrolizumab with respect to DFS as assessed...
